Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
ARA-290 targets peripheral nerve repair and inflammation through the innate repair receptor, while Dihexa works centrally on synaptic architecture
Pharmacokinetic Profile in Research Models DSIP pharmacokinetic characterization in preclinical research reveals properties important for experimental design: Absorption and Distribution: Multiple administration routes: Intravenous, intraperitoneal, intracerebroventricular, intranasal Blood-brain barrier penetration: Limited but detectable CNS entry with systemic administration Peripheral effects: Significant biological activities observed with peripheral administration Tissue distribution: Detected in brain, liver, kidney, and endocrine organs Metabolism and Elimination: Plasma half-life: 15-30 minutes following IV administration Metabolic degradation: Susceptible to peptidase activity Modified analogs: Investigations into metabolically stable DSIP derivatives Biological activity duration: Effects persist beyond plasma presence, suggesting tissue binding or secondary messenger activation Temporal Dynamics: Sleep effects: Observable within 30-90 minutes post-administration Stress-protective effects: Both acute and delayed protective responses documented Circadian interactions: DSIP effects may vary with time of administration Chronic administration: Repeated administration does not produce tolerance in most research models These pharmacokinetic characteristics inform research protocol design, particularly regarding administration timing relative to sleep/wake cycles, stress challenges, or other experimental interventions
This localized inflammation actively degrades the tight junctions holding the enterocytes together
When you're ready to take the next step in your research, we're here to help you Get Started Today
Lets be honest, getting this right in a lab setting is tough
